Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease.

Competing Interests: GGK has received honoraria for speaking from AbbVie, Janssen, Pfizer, Amgen, and Takeda; research support from Ferring, Janssen, AbbVie, GlaxoSmith Kline, Merck, and Shire; and has been a consultant for Gilead. He shares ownership of a patent of treatment of inflammatory disorders, autoimmune disease, and PBC (patent WO2019046959A1, PCT/CA2018/051098). CNB has served on advisory boards for AbbVie Canada, Amgen Canada, Avir Pharmaceuticals, Bristol Myers Squibb Canada, Roche Canada, JAMP Pharmaceuticals Canada, Janssen Canada, Sandoz Canada, Takeda Canada, and Pfizer Canada; is a consultant for Mylan Pharmaceuticals and Takeda; has received educational grants from AbbVie Canada, Pfizer Canada, Takeda Canada, and Janssen Canada; is on the speaker's panel for AbbVie Canada, Janssen Canada, and Takeda Canada; and has received research funding from AbbVie Canada, Amgen Canada, Sandoz Canada, and Pfizer Canada. CM has received consulting fees from AbbVie, Alimentiv, Amgen, Avir Pharmaceuticals, BioJAMP, Bristol Myers Squibb, Celltrion, Ferring, Fresenius Kabi, Janssen, McKesson, Mylan, Takeda, Pendopharm, Pfizer, and Roche; speaker's fees from AbbVie, Amgen, Avir Pharmaceuticals, Alimentiv, Ferring, Janssen, Takeda, and Pfizer; and research support from Ferring and Pfizer. RP has received consulting fees, speaker fees, and research support from AbbVie, Abbott, Alimentiv, Amgen, Arena Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Fresnius Kabi, Galapagos, Genentech, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Mylan, Oppilan Pharma, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Satisfai Health, Sandoz, Schering-Plough, Shire, Sublimity Therapeutics, Theravance Biopharma, Union Chimique Belge, and Takeda. EIB has been a legal consultant for Hoffman La-Roche and Peabody and Arnold and a consultant for McKesson Canada and the Dairy Farmers of Ontario. All other authors declare no competing interests. The work reported here was funded by the Canadian Institutes of Health Research Operating Grant: COVID-19 Rapid Research Funding Opportunity (VR5–172684), the Crohn's and Colitis Canada COVID-19 and IBD Taskforce, the Public Health Agency of Canada Vaccine Surveillance Reference Group and COVID-19 Immunity Task Force, and The Leona M and Harry B Helmsley Charitable Trust Grant (G-2209–05501).